These activities are supported by educational grants from CTI BioPharma Corp and Incyte Corporation.

Agenda

Each 1-hour session will be divided into topic modules focused on current management, emerging research and novel agents and strategies under active investigation for myelofibrosis. Each event will employ an identical format that will include the following elements:

• Moderator Dr Neil Love and a featured participating clinical investigator
• Discussion of participating faculty treatment recommendations
• Review of available clinical research findings
• Community oncologist video case presentations
• Interactive audience polling and extensive Q&A

MODULE 1: Considerations in the Selection of Initial Treatment for Patients with Myelofibrosis (MF)

MODULE 2: Current and Potential Management of MF in Patients with Thrombocytopenia

MODULE 3: Evolving Therapeutic Landscape for Patients with MF and Disease Progression on or Intolerance to Initial JAK Inhibitor Therapy

MODULE 4: Novel Agents and Strategies Under Investigation for MF Beyond JAK Inhibitors

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of myelofibrosis (MF).

Learning Objectives

• Analyze how age, performance status, prior therapeutic exposure and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with primary or postpolycythemia vera/essential thrombocythemia MF.
• Appreciate the FDA approval of fedratinib for intermediate-2- or high-risk primary or secondary MF, and identify patients for whom treatment with this agent is appropriate.
• Assess the tolerability profiles of ruxolitinib and fedratinib, and formulate a side-effect management plan to support quality of life and continuation of treatment.
• Understand the mechanism of action of and available clinical research data with pacritinib for patients with MF and severe thrombocytopenia in preparation for the potential availability of this novel therapeutic approach.
• Appraise available and emerging clinical trial findings with momelotinib for patients with MF, including those with disease-related anemia, and discern the role this agent may have in the disease-management paradigm.
• Recall the biologic rationale for the design of ongoing clinical trials evaluating novel investigational agents and strategies for MF, and refer eligible patients for study participation.

CE Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of each activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Verstovsek has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Prof Harrison — Advisory Committee: AbbVie Inc, AOP Orphan Pharmaceuticals GmbH, Constellation Pharmaceuticals, CTI BioPharma Corp, Galecto, Keros Therapeutics, MorphoSys, Novartis, Roche Laboratories Inc, Sierra Oncology; Consulting Agreements: CTI BioPharma Corp, Galecto, Novartis; Contracted Research: AbbVie Inc, Constellation Pharmaceuticals, CTI BioPharma Corp, Novartis, Sierra Oncology; Data and Safety Monitoring Board/Committee: Galecto, Keros Therapeutics; Speakers Bureau: AbbVie Inc, AOP Orphan Pharmaceuticals GmbH, Bristol-Myers Squibb Company, CTI BioPharma Corp, Geron, Novartis. Dr Mascarenhas — Advisory Committee: Bristol-Myers Squibb Company, Constellation Pharmaceuticals, Geron, Incyte Corporation, Novartis, Roche Laboratories Inc, PharmaEssentia, Sierra Oncology; Consulting Agreements: Celgene Corporation, CTI BioPharma Corp, Kartos Therapeutics, Karyopharm Therapeutics; Contracted Research: AbbVie Inc, Bristol-Myers Squibb Company, Celgene Corporation, CTI BioPharma Corp, Geron, Incyte Corporation, Kartos Therapeutics, Novartis, Roche Laboratories Inc, PharmaEssentia; Data and Safety Monitoring Board/Committee: Galecto.

SURVEY PARTICIPANTS — Bhavana (Tina) Bhatnagar, DO — Advisory Committee and Consulting Agreements: Celgene Corporation, CTI BioPharma Corp, Pfizer Inc; Contracted Research: Cell Therapeutics Inc, Karyopharm Therapeutics, Sumitomo Dainippon Pharma Oncology Inc. Aaron T Gerds, MD, MS — Advisory Committee: AbbVie Inc, Bristol-Myers Squibb Company, CTI BioPharma Corp, Imago BioSciences, MorphoSys, Novartis, PharmaEssentia, Sierra Oncology. Brady L Stein, MD, MHS — Advisory Committee: Constellation Pharmaceuticals, PharmaEssentia.

SERIES MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
These activities are supported by educational grants from CTI BioPharma Corp and Incyte Corporation.